Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Diwuyanggan (DWYG) is a traditional Chinese medicine (TCM) prescription formulated as a hospital preparation and authorized drug in China. It consists of five herbal extracts in specific proportions by weight: Rehmannia glutinosa (20%), Artemisia scoparia (33.3%), Curcuma longa (13.4%), Schisandra chinensis (20%), and Glycyrrhiza uralensis (13.4%)[6][1]. DWYG has been studied for its effects on liver diseases, including hepatitis and hepatocellular carcinoma, with reported activities such as regulating liver regeneration, modulating immune responses, ameliorating liver injury and fibrosis, antiviral effects, and suppressing hepatic cancer[6][8][2]. Mechanistically, it appears to act through modulation of the hepatic stem cell microenvironment and regulation of signaling pathways such as Ras/Raf/Mek/Erk[9], reversing gene expression changes associated with liver injury or cancer[8]. Over 200 compounds have been identified within the formulation using advanced mass spectrometry techniques[8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on diwuyanggan.